Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN
Supernus Pharmaceuticals — Investor Presentation (May 2026)
35 slides from Supernus Pharmaceuticals's investor presentation, May 2026
Slide 1: Supernus Pharmaceuticals Corporate Overview
Supernus Pharmaceuticals Corporate Overview May 2026 © 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Supernus’ business strategy, goals and expec
Slide 3: Proven Execution in CNS
Proven Execution in CNS 30+ Years of CNS Experience Building for the Long-Term with Four Growth Drivers 2005 - Present 1997 - 2005 Prior to becoming independent in 2005, Supernus operated as Shire Laboratories, Inc., a division of Shire. All trademarks are the property of their respective owners © 2
Slide 4: Proven Commercial Execution
Proven Commercial Execution Total Portfolio Revenue Growth Total Revenues ($ millions) Trokendi XR® Oxtellar XR® LOE 840 – 870* 719 667 662 608 580 520 409 393 302 215 147 93 12 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 *Guidance provided on May 5, 2026 LOE = Loss of Excl
Slide 5: Portfolio Diversification and Management of LOEs
Portfolio Diversification and Management of LOEs % of Net Product Sales^ 2019 1Q 2026 3 5 5 4 Trokendi XR 4 23 Oxtellar XR Qelbree Trokendi XR 16 GOCOVRI Oxtellar XR ZURZUVAE 44 APOKYN 77 20 Other ONAPGO 5 ^Includes collaboration revenue from ZURZUVAE © 2026 Supernus Pharmaceuticals, Inc. All Rights
Slide 6: Strategic Direction
Strategic Direction Multi-Billion High Dollar Market Value Market Value Build a Capitalize Complete Multi-Billion Corporate on our Development Dollar CNS Development Strong SPN-817 Franchise R&D SPN-820 Capability Low Key Strategic Imperatives © 2026 Supernus Pharmaceuticals, Inc. All Rights Reserve
Slide 7: Significant Experience & Capabilities in Drug Development
Significant Experience & Capabilities in Drug Development Discovery Platform Design and synthesis of Discovery new compounds based on structure, function In vitro, PK, and disease pathways Concept preclinical proof of Validation concept, and stability studies Safety Toxicology In-house CMC/drug CMC
Slide 8: Robust CNS Pipeline to Drive Long-Term Growth
Robust CNS Pipeline to Drive Long-Term Growth Program Indications Discovery Preclinical Phase 1 Phase 2 Phase 3 Filing Market SPN-817 Epilepsy SPN-820 Depression SPN-443 ADHD Zuranolone PPD (EU) Zuranolone MDD (Japan) PPD = Postpartum Depression MDD = Major Depressive Disorder © 2026 Supernus Pharma
Slide 9: Novel Non-Stimulant ADHD Product
Novel Non-Stimulant ADHD Product 1Q 2026 growth of 20% in net sales and 19% in prescriptions compared to 1Q 2025 IP expirations from 2029-2035 Net Sales ($ millions) 305 241 140 61 10 2021 2022 2023 2024 2025 © 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. 9
Slide 10: ADHD Market By Patient Population
ADHD Market By Patient Population 2025 Total U.S. ADHD Market – 111 Million Prescriptions % of Market 31% 69% Adult Ped/Adolescent 10 Source: IQVIA © 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. 10
Slide 11: Source of Usage
Source of Usage 68% of Patients Were Prescribed Qelbree As Replacement to Existing Therapy or Add-on Patients Who Switched to Qelbree Came From: 32% Stimulants 55%: •Vyvanse®: 24% •AMP ER/Adderall XR®: 17% •MPH ER/Concerta®: 25% 68% •MPH IR: 8% •AMP IR: 12% •DEXMPH/Focalin®: 13% •Other: 1% Non-Stimu
Slide 12: vs. Atomoxetine
vs. Atomoxetine Research Article, Published in CNS Drugs (July 2023) Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder Authors: Maxwell Z Price, Richard L Price ------------------------------------------------------------------------------------------
Slide 13: vs. Atomoxetine
vs. Atomoxetine Research Article, Published in CNS Drugs (July 2023) Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder Authors: Maxwell Z Price, Richard L Price ------------------------------------------------------------------------------------------
Slide 14: Top Reasons to Try Qelbree
Top Reasons to Try Qelbree® Patients Having Issues With Stimulants & Looking For an Effective Non-Stimulant Reasons that led Healthcare Provider to try Qelbree Patient currently on a stimulant and experiencing side 65% effect issues Patient has tried several stimulants and stimulants do 60% not work
Slide 15: Major Presence in Parkinson's Disease (PD)
Major Presence in Parkinson’s Disease (PD) 1 Million U.S. PD Patients - Market Expected to Grow to $6.2B by 2026 (1) Stage 1 Stage 1.5 Stage 2 Stage 2.5 Stage 3 Stage 4 Stage 5 Pen Advanced continuous treatments On‐demand L‐dopa Therapy Adjuncts Monotherapy Generic Levodopa Initial Symptoms © 2026 S
Slide 16: Unique Positioning in PD
Unique Positioning in PD 1Q 2026 growth of 15% in net sales and 7% in prescriptions compared to 1Q 2025 Only product indicated to treat both dyskinesia and “off” episodes Indications: ‒ For the treatment of dyskinesia in patients with PD receiving levodopa- based therapy, with or without concomitant
Slide 17: Significantly Decreased Dyskinesia and OFF Time
Significantly Decreased Dyskinesia and OFF Time, Thereby Significantly Increasing Good ON Time GOCOVRI achieved reductions in dyskinesia & OFF episodes without having to adjust levodopa dose Primary endpoint Secondary endpoints Placebo-adjusted, pooled results from pivotal trials* 27% C 36% 29% DECR
Slide 18: Novel Apomorphine Subcutaneous Infusion Device
Novel Apomorphine Subcutaneous Infusion Device Launched April 2025 First and only apomorphine subcutaneous infusion device Non‐invasive dopaminergic stimulation therapy for continuous treatment of ON-OFF episodes in PD Currently available options ‒ Gastro-intestinal surgically implanted levodopa/car
Slide 19: Novel Apomorphine Subcutaneous Infusion Device
Novel Apomorphine Subcutaneous Infusion Device Phase 3 Study Results 12-week, double-blind, multi-center, randomized, pbo-controlled (N=107) Primary Endpoint ONAPGO demonstrated a 2.6-hour reduction in daily OFF time compared to placebo (0.9 hour); p= 0.0114 Secondary Endpoint ONAPGO demonstrated a
Slide 20: PPD Poses a Substantial Burden to Patients and their Families
PPD Poses a Substantial Burden to Patients and their Families Estimated that about 1 in 8 women with a recent live birth experience symptoms of PPD, or roughly ~500K women a year1-2 (~100K treated ea. year) 1. Bauman BL, Ko JY, Cox S, D’Angelo Mph DV, Warner L, Folger S, Tevendale HD, Coy KC, Harris
Slide 21: The First & Only Oral Treatment Specifically Indicated for Women with PPD
The First & Only Oral Treatment Specifically Indicated for the Treatment of Women with PPD Potential for Rapid & Sustained Improvement In the SKYLARK and ROBIN Studies, an improvement in depressive symptoms vs. placebo was seen with a 14- day treatment course as early as day 3 and maintained at da
Slide 22: Continued Strong Growth 1Q 2026
Continued Strong Growth 1Q 2026 Collaboration revenue from ZURZUVAE of $27.6 million in 1Q 2026^ ‒ US sales of ZURZUVAE, as reported by Biogen Inc., increased ~100% in 1Q 2026 compared to 1Q 2025 ‒ Prescriptions increased by 82% in 1Q 2026 compared to 1Q 2025 Continued strong growth in patient deman
Slide 23: SPN-817
SPN-817 Only AChE Inhibitor in Development for Focal Seizures Huperzine A is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor, an enzyme that metabolizes acetylcholine (ACh) after synaptic release1,2 Inhibition of AChE increases extracellular levels of ACh ACh augmentation ac
Slide 24: SPN-817: Phase 2a Study Design
SPN-817: Phase 2a Study Design Design: Phase 2a, open-label, flexible-dose, safety and tolerability exploratory study Sample size: 41 adult subjects with treatment resistant seizures ‒ At least 4 motor seizures during screening - median baseline seizure frequency was 11.3 ‒ Took at least one concomi
Slide 25: SPN-817: Phase 2a Endpoints
SPN-817: Phase 2a Endpoints Primary Safety Endpoints ‒ Adverse events (AEs) ‒ AEs leading to discontinuation Key Secondary/Exploratory Endpoints ‒ Percent CFB in quantifiable motor seizure frequency per 28 days throughout SPN-817 dosing during maintenance period/OLE ‒ Treatment response defined as ≥
Slide 26: SPN-817: Phase 2a Safety and Tolerability
SPN-817: Phase 2a Safety and Tolerability Maintenance Titration Period Period Category (n=41) (n=26) n (%) n (%) Subjects with at least one treatment related TEAE 39 (95.1) 13 (50.0) Subjects with any treatment related serious AE* 1 (2.4) 0 Maximum severity of treatment related TEAE** Mild 19 (46.3)
Slide 27: SPN-817: Phase 2a Treatment Related TEAEs
SPN-817: Phase 2a Safety and Tolerability; Treatment Related TEAEs (≥5% incidence) Titration Period Maintenance Period Preferred Term Treatment related TEAEs (n=41) (≥5% incidence) (n=26) n (%) n (%) Subjects with at least one TEAE 39 (95.1) 13 (50.0) Nausea* 20 (48.8) 2 (7.7) Diarrhoea 10 (24.4) 3
Slide 28: SPN-817: Phase 2a Efficacy in Focal Seizures
SPN-817: Phase 2a Efficacy in Focal Seizures for Maximum Dose 3-4 mg BID Group Percent Reduction from Baseline in Seizure Frequency © 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. 28
Slide 29: SPN-817: Phase 2a Response Rate in Focal Seizures
SPN-817: Phase 2a Response Rate in Focal Seizures for Max. Dose 3-4 mg BID Group © 2026 Supernus Pharmaceuticals, Inc. All Rights Reserved. 29
Slide 30: CGI and EpiTrack Results in Focal Seizures
CGI and EpiTrack Results in Focal Seizures End of Maintenance Baseline End of Maintenance Secondary Outcome Measure Mean (SD) Mean (SD) CFB Mean (SD) CGI-S Score, 3.6 (1.24) 2.7 (0.81) -0.7 (1.20) EpiTrack® assessment of cognition ‒ 12/16 (75%) improved or unchanged ‒ 3 subjects improved from “signi
Slide 31: SPN-817: Summary
SPN-817: Summary Phase 2a open label data suggest a highly differentiated clinical profile Safety & Tolerability ‒ Most TEAEs occurred during titration ‒ Exploring mitigation strategies to minimize discontinuations during titration ‒ In maintenance period, SPN-817 was well tolerated with 7.7% disc
Slide 32: SPN-817: Summary (cont'd)
SPN-817: Summary (cont’d) Efficacy – High response rates in post-maintenance period – 83% of subjects had 30% or more seizure reduction – 67% of subjects had 50% or more seizure reduction – 50% of subjects had 75% or more seizure reduction – Seizure Freedom – Maintenance period: 10% of subjects wh
Slide 33: SPN-820
SPN-820 Novel MOA for Treatment of Depression Oral product candidate for the treatment of depression Novel, first in class, intracellular modulator of mTORC1 ‒ Restores mTORC1 synaptic signaling through a unique intracellular mechanism Increased dendritic spines in animal model supporting neuroplast
Slide 34: Full Year 2026 Financial Guidance
Full Year 2026 Financial Guidance1 ($ millions) Total Revenues, Includes: ONAPGO net sales of $45M-$70M $840 - $870 Trokendi XR and Oxtellar XR net sales of $40M-$50M Combined R&D and SG&A Expenses $620 - $650 Operating Earnings (Loss) – GAAP $0 – $30 Adjustments: Amortization of intangible asse
Slide 35: Positioned For Strong Growth
Positioned For Strong Growth Growth Potential of Qelbree® GOCOVRI®, ZURZUVAE® and ONAPGO Innovative R&D Portfolio SPN-817 First in Class Novel MOA for Epilepsy SPN-820 First in Class Novel MOA for Depression SPN-443 Novel Stimulant for ADHD Corporate Development © 2026 Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals — Investor Presentation (May 2026) on 6ix